Evidence map›Paper›PMID 37210419›Full record

ArticleScientific reports2023

Identification of a mycobacterial hydrazidase, an isoniazid-hydrolyzing enzyme.

Arata Sakiyama, Chaogetu Saren, Yukihiro Kaneko, Ken-Ichi Oinuma

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Arata SakiyamaDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
Chaogetu SarenDepartment of Bacteriology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
Yukihiro KanekoDepartment of Bacteriology, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
Ken-Ichi OinumaDepartment of Bacteriology, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan. kioinuma@omu.ac.jp.
Osaka City University · JPOsaka Metropolitan University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There exists decades-old evidence that some mycobacteria, including Mycobacterium avium and Mycobacterium smegmatis, produce hydrazidase, an enzyme that can hydrolyze the first-line antitubercular agent isoniazid. Despite its importance as a potential resistance factor, no studies have attempted to reveal its identity. In this study, we aimed to isolate and identify M. smegmatis hydrazidase, characterize it, and evaluate its impact on isoniazid resistance. We determined the optimal condition under which M. smegmatis produced the highest amount of hydrazidase, purified the enzyme by column chromatography, and identified it by peptide mass fingerprinting. It was revealed to be PzaA, an enzyme known as pyrazinamidase/nicotinamidase whose physiological role remains unknown. The kinetic constants suggested that this amidase with broad substrate specificity prefers amides to hydrazides as a substrate. Notably, of the five tested compounds, including amides, only isoniazid served as an efficient inducer of pzaA transcription, as revealed by quantitative reverse transcription PCR. Moreover, high expression of PzaA was confirmed to be beneficial for the survival and growth of M. smegmatis in the presence of isoniazid. Thus, our findings suggest a possible role for PzaA, and other hydrazidases yet to be identified, as an intrinsic isoniazid resistance factor of mycobacteria.

Indexed as

MycobacteriumMycobacterium tuberculosisAmidesAntitubercular AgentsIsoniazidMycobacterium smegmatisAmidesAntitubercular AgentsIsoniazid

Identifiers

PMID37210419
PMCPMC10199920
OpenAlexW4377157346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.